ESR1 and prostate carcinoma: At present, several PROTAC drugs have undergone or are undergoing clinical trials, including ARV-110 [3] which targets the androgen receptor in prostate cancer, ARV-471 [4], targeting the estrogen receptor in breast cancer, and FHD-609 which targets BRD9 in Synovial sarcoma.